Inverness Medical device ‘helps to detect patients with AKI’

Inverness Medical has pointed out the results of a trial which found that the firm’s Triage NGAL Test is effective in determining which intensive care unit patients are at risk due to acute kidney injury (AKI).

The study, which was conducted in Vicenza in Italy, tested blood samples collected by an intensive care unit using the Triage NGAL Test.

Published in the journal Intensive Care Medicine, the novel bedside blood test measured in critically ill patients being admitted to the intensive care unit was found to significantly help towards identifying which patients have AKI.

Professor Claudio Ronco of the San Bartolo Hospital in Vicenza commented: “We are living in an exciting era where it seems possible to diagnose AKI much earlier than before thanks to NGAL – a new promising biomarker of kidney damage.”

In other Inverness Medical news, the firm published its financial results for the third quarter of 2009 in October, revealing net revenue of $535.8 million (326.2 million pounds) for the period, compared to $438.8 million for the corresponding period of 2008.